Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Triple Negative Breast Neoplasms 14Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 4Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Metastatic Urothelial Cancer 1Metastatic Solid Tumors 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1Glioblastoma 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

pembrolizumab 44Paclitaxel 37Carboplatin 30Doxorubicin 11Cisplatin 11Bevacizumab 11lenvatinib 9Nivolumab 9Docetaxel 9Fulvestrant 8Gemcitabine 7Oxaliplatin 6Fluorouracil 6Pemetrexed 5Letrozole 5Ipilimumab 5Cetuximab 5spartalizumab 4selinexor 4dostarlimab 4Trastuzumab 4Irinotecan 4trastuzumab deruxtecan 3tisotumab vedotin 3serabelisib 3sacituzumab govitecan 3ribociclib 3olaparib 3epacadostat 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Endometrial Neoplasms × sacituzumab govitecan × Clear all
NCT06486441 2026-01-15

ASCENT-GYN-01

Gilead Sciences

Phase 3 Active not recruiting
640 enrolled
Gynecologic

Endometrial Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
430 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡